Compound C41 Normalizes APP Processing to Reduce Alzheimer's Amyloid Plaques
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease primarily focus on reducing amyloid-beta peptide levels without addressing the underlying imbalance in physiological signaling processes, leading to limited cognitive improvement and an incomplete understanding of the disease's pathogenesis.
Innovation Solution
Development of compound C41, which promotes the non-amyloidogenic processing of amyloid precursor protein (APP) to increase sAPPα levels, inhibiting the amyloidogenic pathway and reducing the production of neurotoxic Aβ peptides, thereby addressing the imbalance in APP processing and signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If therapies focus on reducing Aβ levels, then amyloid plaque levels are reduced, but cognitive improvement is limited
Solution Approach 1:
The invention extracts and removes the harmful C31 peptide fragment and APPneo fragment produced by caspase cleavage of APP, preventing their accumulation and neurotoxic effects. This is achieved through therapeutic agents that block caspase-mediated cleavage or promote degradation of these fragments, thereby addressing the root cause of neuronal death rather than just removing Aβ plaques
Solution Approach 2:
Instead of focusing on reducing Aβ levels as the primary therapeutic target, the invention inverts the approach by targeting the upstream caspase cleavage event that produces the C31 and APPneo fragments. This reverses the conventional wisdom that Aβ reduction alone is sufficient, and instead addresses the fundamental signaling imbalance in APP processing that leads to both Aβ production and neuronal death
2Object-affected harmful factors
If Aβ is viewed as toxic peptide, then Aβ reduction is prioritized, but physiological signaling role is neglected
Solution Approach 1:
The invention segments the APP processing pathway into distinct events: α-secretase cleavage (producing sAPPα, non-toxic), β-secretase cleavage (producing Aβ, potentially toxic), and caspase cleavage (producing C31 and APPneo fragments, neurotoxic). By specifically targeting the caspase cleavage segment, the therapy eliminates the most harmful fragments while preserving the physiological signaling functions of sAPPα and regulated Aβ production
Solution Approach 2:
The invention introduces therapeutic agents that act as intermediaries to block caspase-mediated cleavage of APP. These agents prevent the formation of C31 and APPneo fragments without interfering with the normal physiological processing of APP through α-secretase or β-secretase pathways, thus maintaining the balance between toxic and physiological functions
3Productivity
If caspase cleavage of APP is increased, then Aβ production occurs, but neuronal cell death is promoted
Solution Approach 1:
The invention converts the harmful caspase cleavage event into a beneficial therapeutic target. By blocking caspase-mediated cleavage of APP, the therapy prevents the production of neurotoxic C31 and APPneo fragments while allowing normal APP processing to continue. This transforms a pathogenic mechanism into a therapeutic intervention point, converting the harm of caspase activation into benefit by inhibiting its detrimental effects
Data Source
Figure 1~2
Figure 3~4
Figure 5
AI summary
In various embodiments, compositions and methods are provided for treatment and/or prevention of amyloidogenic diseases. In certain embodiments, the methods entail administering an effective amount of compound C41 to a subject in need thereof for prophylactic or therapeutic effect. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In certain embodiments, methods of reducing the risk, lessening the severity, or delaying the progression or onset of a disease characterized by beta-amyloid deposits in the brain of a mammal are also provided. In certain embodiments, methods of directly or indirectly enhances sAPPα, lowers Aβ, p-Tau, inhibits the C-terminal cleavage of APP resulting in the formation of APP-C31 peptide and APPneo (APP664) and improves memory in a mammal are provided.